hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06299176 id: ESHF-WHRT (2024-10362) briefTitle: Whole Heart Radiotherapy for End-stage Heart Failure acronym: ESHF-WHRT overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-07 date: 2024-03-07 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses. Management focuses on controlling symptoms, correcting precipitants, avoiding triggers, and improving quality-of-life. The combination of recent preclinical and clinical data suggests that localized cardiac RT is relatively safe and has positive conductive and anti-proliferative effects in the "sick" heart. In this Phase 1 study, the investigators aim to assess the feasibility and safety of 5 Gy whole heart radiotherapy in six (6) ESHF participants with limited options for further medical therapy to control their disease. The investigators hypothesize that 5 Gy whole heart radiotherapy can improve LVEF and decrease blood markers of heart failure and inflammation including B-type natriuretic peptide (BNP), C-reactive protein (CRP), and troponins, while also having a very tolerable side effect profile. conditions: Heart Failure NYHA Class III conditions: Heart Failure NYHA Class IV conditions: End-stage Heart Failure conditions: Heart Failure With Reduced Ejection Fraction studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 6 participants with end-stage heart failure (NYHA 3 or 4, LVEF \< 30%) with no other standard of care therapy options to receive whole heart radiation therapy. primaryPurpose: TREATMENT masking: NONE maskingDescription: no masking count: 6 type: ESTIMATED name: Whole Heart Radiation Therapy measure: Change in mean left ventricle ejection fraction measure: Acute adverse events definitely or probably related to radiation therapy at 30 days as per CTCAE v 5.0 measure: Overall survival measure: Hospital stays measure: Subacute adverse events measure: Late adverse events measure: Medication Changes - dose measure: Medication Changes - number measure: Quality of life CHFQOLQ-20 measure: Quality of life - SF-36 measure: Troponin changes measure: Lactate changes measure: Renal Function measure: b-natrurietic peptide sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299150 id: 2023-1 briefTitle: Clinical Evaluation of Three Different Techniques Restoring Ellis Class II Traumatized Central Incisors In Children overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-05-01 date: 2025-02-01 date: 2024-03-07 date: 2024-03-07 name: October University for Modern Sciences and Arts class: OTHER briefSummary: Dental trauma (DT) of the incisors and their supporting tissues, which is one of the most challenging dental emergency situations, requires immediate assessment and management due to psychological and physical reasons. (8) This is especially important for young permanent teeth because of continuing development in order to minimize undesired complications. The treatment of dental trauma is sometimes neglected. (9,10) although it might lead to pain, difficulty in articulation and mastication as well as having considerable negative effects on patient's self-esteem. (11) However, aesthetics of the anterior teeth are very important aspects of human appearance and could be affected by many factors including the presence of fillings, tooth color, position, alignment, shape and number. (12)
As the maxillary incisors are the most commonly injured teeth due to their exposed position, a functional, aesthetic and time-efficient restoration is frequently demanded.(15) According to the current International Association of Dental Traumatology guidelines, crown fractures confined to enamel and dentine may be treated either with a direct composite restoration or with an adhesive reattachment of the fractured fragment.(16) As long as the fragment is intact, reattachment is often preferred in dental practice. This technique facilitates the restoration of the tooth with its original anatomy, color and function in a minimum amount of time. (17,18) Unfortunately, clinical studies regarding the survival of reattached fragments are scarce, and results from laboratory investigations cannot be transferred to clinical settings without limitations. (19) Furthermore, longevity data of direct composite restorations in fractured anterior teeth are restricted to a few clinical studies. (20, 21)
In addition to the aforementioned restorative alternatives, the use of small partial glassy restorations-partial laminate veneers (PLVs), sectional veneers, or ceramic fragments-has become increasingly popular over the last few years. (22,23) PLVs are thin pieces of glass-matrix ceramic fragments without a defined shape that are used to restore small defects in the anterior teeth. As tooth preparation is not required for this type of restoration, as for conventional laminate veneers, and minimal to no prep is accepted, the maximum amount of enamel surface structure is conserved. (24) Thus, retention relies completely on adhesion, which is primarily achieved by bonding to the conditioned glassy surface. (25,26) Despite their growing popularity, available data in the literature on PLVs are limited to a few in vitro studies (27,28) and case reports (29, 30, 31), without any clinical information available at present.
Patients in all groups will receive a minimally invasive restoration with high esthetic advantages and long-term success of their fractured incisors (either conventional composite restoration, fragment reattachment or partial laminate veneers) that require minimal to no preparation depends on the type of restoration will receive and doesn't require local anesthesia. conditions: Composites Resins studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study is a randomized clinical trial (RCT) where 2 arm parallel groups with a 1:1 allocation ratio were compared. The child participants and the legal guardian of each participating child and the statistician were blinded. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: IPS e.max CAD measure: Clinical success/ survival sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06299137 id: RE2022-0000000349 id: RE2022-0000000349 type: OTHER_GRANT domain: Society of Academic Emergency Medicine briefTitle: Ultrasound Guided Serratus Anterior Plane Block in ED Patients With Rib Fractures overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-10 date: 2025-10 date: 2024-03-07 date: 2024-03-12 name: Rhode Island Hospital class: OTHER briefSummary: The goal of this clinical trial is to test the effectiveness of the Serratus Anterior Plane Block in patients with rib fractures. The main questions it aims to answer are:
Participants will undergo the Serratus Anterior Plane. Researchers will compare this to usual care to see if this intervention improves pulmonary function and reduces opioid requirements for ED patients with rib fractures. conditions: Rib Fractures conditions: Pain Acute conditions: Regional Anesthesia conditions: Opioid Use studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Research Assistants who collect the data will be blinded to which arm of the study the participants are in. whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Serratus Anterior Plane Block name: Ropivacaine injection measure: PIC Score measure: Total oral morphine equivalents over the first 24 hours sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rhode Island Hospital city: Providence state: Rhode Island zip: 02903 country: United States name: Leland K Perice, MD role: CONTACT phone: 401-429-3441 email: lperice@lifespan.org name: Leland K Perice, MD role: PRINCIPAL_INVESTIGATOR lat: 41.82399 lon: -71.41283 hasResults: False
nctId: NCT06299124 id: RGT-419B-102 briefTitle: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors overallStatus: RECRUITING date: 2023-04-17 date: 2024-12-30 date: 2025-06-30 date: 2024-03-07 date: 2024-03-08 name: Regor Pharmaceuticals Inc. class: INDUSTRY briefSummary: This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors. conditions: Breast Cancer conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: RGT-419B measure: Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level measure: Safety & Tolerability - Incidence, Severity, and Causality of all Treatment Emergent Adverse Events (TEAEs) measure: Day 1 and steady-state pharmacokinetics(PK) assessment of RGT-419B and major metabolites - Cmax measure: Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Area Under Concentration-TimeCurve to Infinity (AUC0-inf) measure: Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Plasma Decay Half-Life (t1/2) measure: Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Time to Reach Maximum ObservedPlasma Concentration (Tmax) measure: Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Accumulation rate after multipledoses measure: Day 1 and steady-state PK assessment of RGT-419B and major metabolites - Cumulative urinary excretion measure: Tumor Response assessed by Investigator according to RECIST v1.1 measure: QTc Interval - Changes in corrected QT interval sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center status: RECRUITING city: Shanghai state: Shanghai zip: 200032 country: China name: Yan Zhou role: CONTACT phone: 86-021-31168233 lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06299111 id: R9933-DVT-2308 id: 2023-508603-21-00 type: OTHER domain: EU CT Number briefTitle: A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) acronym: ROXI-CATH overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2026-06-08 date: 2026-06-08 date: 2024-03-07 date: 2024-03-07 name: Regeneron Pharmaceuticals class: INDUSTRY briefSummary: This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in your vein, also called a 'PICC line'.
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) conditions: Venous Thromboembolism studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 195 type: ESTIMATED name: REGN9933 name: REGN7508 name: Placebo measure: Incidence of confirmed VTE per central reading center (CRC) review measure: Incidence of treatment-emergent adverse event (TEAEs) measure: Severity of TEAEs measure: Incidence of confirmed PICC associated venous thrombosis per CRC review measure: Incidence of major bleeding measure: Incidence of clinically relevant non-major (CRNM) bleeding measure: Concentrations of REGN9933 in serum measure: Concentrations of REGN7508 in serum measure: Change in activated partial thromboplastin time (aPTT) measure: Change in prothrombin time (PT) measure: Incidence of anti-drug antibody (ADA) to REGN9933 over time measure: Titer of ADA to REGN9933 over time measure: Incidence of ADA to REGN7508 over time measure: Titer of ADA to REGN7508 over time sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299098 id: R1033-OB-2288 briefTitle: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss acronym: COURAGE overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-13 date: 2026-06-24 date: 2026-06-24 date: 2024-03-07 date: 2024-04-01 name: Regeneron Pharmaceuticals class: INDUSTRY briefSummary: This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). Part A of the study, the sponsor is only researching trevogrumab. Part B of the study the sponsor is researching trevogrumab, garetosmab, and Wegovy either alone or in different combinations with each other. Part A of the study is focused on healthy participants. Part B of the study is focused on participants with obesity. The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B of the study is to see how safe and effective the study drug is when combined with Wegovy.
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) conditions: Obesity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 624 type: ESTIMATED name: Trevogrumab-Part A name: Trevogrumab-Part B name: Garetosmab name: Semaglutide name: Matching Placebo-Part A name: Matching Placebo-Trevogrumab name: Matching Placebo-Garetosmab measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Severity of TEAEs measure: Percent body weight change measure: Percent change in total fat mass measure: Concentrations of trevogrumab in serum over time measure: Percent body weight change measure: Percent change in total fat mass measure: Percent change in total lean mass measure: Change in waist circumference (cm) measure: Percent change in body weight measure: Percent change in total lean mass measure: Percent change in regional measurements of body composition measure: Percent change in gynoid fat mass measure: Change in total lean mass:total fat mass ratio measure: Proportion of weight loss attributable to fat mass loss measure: Percent change in android (central) fat mass measure: Percent change in thigh muscle volume (TMV) measure: Body weight reduction of ≥5% measure: Body weight reduction of ≥10% measure: Body weight reduction of ≥15% measure: Body weight reduction of ≥20% measure: Body weight reduction of ≥25% measure: Percent change in fasting serum triglycerides measure: Percent change in total cholesterol measure: Percent change in Apolipoprotein B (Apo B) measure: Percent change in low-density lipoprotein cholesterol (LDL-C) measure: Change in physical function domain (5 items) score of Impact of Weight on Quality of Life-Lite for Clinical Trials (IWQoLLite- CT) measure: Change in physical functioning domain score of SF-36 measure: Concentrations of garetosmab in serum over time measure: Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time measure: Titer of ADAs to trevogrumab after repeated doses over time measure: Incidence of ADAs to garetosmab after repeated doses over time measure: Titer of ADAs to garetosmab after repeated doses over time measure: Incidence of TEAEs measure: Severity of TEAEs sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ProSciento city: Chula Vista state: California zip: 91911 country: United States lat: 32.64005 lon: -117.0842 facility: Tandem Clinical Research city: Marrero state: Louisiana zip: 70072 country: United States lat: 29.89937 lon: -90.10035 facility: Accellacare of Wilmington city: Wilmington state: North Carolina zip: 28401 country: United States lat: 34.22573 lon: -77.94471 hasResults: False
nctId: NCT06299085 id: OSTEO-BS (L4191) briefTitle: Clinical-functional Effects of Bariatric Surgery on the Musculoskeletal System in Relation to Bone Turnover. overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-10-31 date: 2026-03-01 date: 2024-03-07 date: 2024-03-07 name: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio class: OTHER briefSummary: By studying "in vivo" new possible predictive factors of increased bone turnover and risk of fractures after bariatric surgery, our study aims to improve health not only musculoskeletal but general of patients with severe obesity, a pathology which represents one of the main causes of disability and mortality. conditions: Bariatric Surgery Candidate studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The minimum sample size was determined by considering the circulating levels of gastro-entero hormones (PYY, ghrelin, GLP-1, GIP), adipokines (leptin and adiponectin) and hormones associated with the anabolism of muscle and bone tissue (insulin). as primary endpoints; the highest calculated sample size obtained for ghrelin levels was used for the purposes of this study.
The resulting minimum sample size is 42 patients. Taking into account the presence of any drop-outs, 20% more patients will be considered, for a total of 50 patients to be enrolled. primaryPurpose: SCREENING masking: NONE count: 50 type: ESTIMATED name: 50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery. measure: Study of new predictive markers of possible bone remodeling through specific blood tests before (pre-admission) and 12 months after bariatric surgery. measure: Evaluation of the bone health status of patients pre- and post-bariatric surgery using different methods. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06299072 id: PEP-2303 briefTitle: A Cross-sectional Online Survey Among Saudi Arabian Population in the Age Group 18-40 Years to Assess Whole Grain (WG) Awareness, Consumption Levels, and Dietary Habits Around Breakfast overallStatus: COMPLETED date: 2023-09-05 date: 2023-09-19 date: 2023-09-19 date: 2024-03-07 date: 2024-03-12 name: PepsiCo Global R&D class: INDUSTRY briefSummary: In this online survey conducted suing the YouGov consumer insights panel, the primary aims of this study are to provide for the first time an estimate of consumer awareness regarding wholegrains; their definitions and knowledge of potential benefits in the Saudi Arabia adult population and the he estimated consumption amongst Saudi consumers.
Secondary Objectives are to assess the breakfast habit, oat consumption \& health concerns amongst Saudi consumers; identify socio-demographic and consumer characteristics associated with breakfast consumption, the types of foods consumed at breakfast, and fill gaps in knowledge regarding breakfast eating habits, commonly consumed breakfast foods. conditions: Diet, Healthy studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 814 type: ACTUAL name: Survey measure: Consumer awareness regarding wholegrains measure: Consumer definitions of wholegrains measure: Consumer knowledge of potential benefits of wholegrains measure: Wholegrain consumption measure: Breakfast habits measure: Oat consumption measure: Health concerns measure: Socio-demographics associated with breakfast consumption measure: Consumer characteristics associated with breakfast consumption measure: Types of foods consumed at breakfast measure: Fill gaps in knowledge regarding breakfast eating habits measure: Commonly consumed breakfast foods sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Remote, no facility visits city: Riyadh country: Saudi Arabia lat: 24.68773 lon: 46.72185 hasResults: False
nctId: NCT06299059 id: Compliance briefTitle: Intermittent Oro-esophageal Tube on Rehabilitation Therapy Compliance in Stroke Patients overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-07 date: 2024-07 date: 2024-03-07 date: 2024-03-12 name: Zeng Changhao class: OTHER briefSummary: The aim of this clinical trial is to compare Rehabilitation Therapy Compliance of ischemic stroke patients who receive enteral nutrition support through either Intermittent Oro-esophageal Tube or Nasogastric Tube. Patients will be randomly assigned to either an observation group or a control group, with both groups receiving routine rehabilitation treatment. The observation group will receive enteral nutrition support through Intermittent Oro-esophageal Tube, while the control group will receive it through Nasogastric Tube. Researchers will then compare Rehabilitation Therapy Compliance of the two groups. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Intermittent Oro-esophageal Tube Feeding name: Nasogastric Tube Feeding measure: Rehabilitation Treatment Compliance Questionnaire measure: Patient Health Questionnaire-9 measure: Swallowing Quality of Life questionnaire sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299046 id: 3235 briefTitle: Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study acronym: UROBLOOD01 overallStatus: COMPLETED date: 2022-12-01 date: 2023-01-01 date: 2023-01-01 date: 2024-03-07 date: 2024-03-08 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: Nowadays robot-assisted radical prostatectomy (RARP) has become the standard surgical treatment for localised prostate cancer. The robotic approach has been proven superior to open retropubic prostatectomy (ORP) in terms of surgical-related morbidity: RARP has in fact been associated with significantly lower estimated blood loos (EBL), lower transfusion rate, less length of stay, shorter catheterization time, lower risk of Clavien-Dindo grade II and III complications, lower risk of vesicourethral anastomotic stricture and less post-operative pain. The optimal anatomical visualisation and the extraordinary maneuverability, along with the tamponade effect of the pneumoperitoneum, are surely to be deemed responsible of this statistically significant differences.
The investigators retrospectively evaluated all the patients that underwent robot-assisted radical prostatectomy in our Urology Unit from the 1st of January 2017 to the 31th of December 2020. The investigators collected demographic, clinical and pathological data from the medical records of these patients, with particular attention to other known risk-factors for RARP-associated bleeding (e.g.: volume of the prostate, body mass index, smoking status, nerve sparing technique).